IRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IRadimed Corp (IRMD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial growth and positive analyst sentiment, the technical indicators and insider selling trends suggest caution. Additionally, there are no significant trading signals or news catalysts to justify immediate action.
The MACD histogram is negative and expanding, suggesting bearish momentum. RSI is neutral at 39.41, and moving averages are converging, indicating no clear trend. The stock is trading near its S1 support level of 98.099, with resistance at 102.867.
Strong Q4 financial performance with revenue up 17.03% YoY, net income up 25.16% YoY, and EPS up 25.00% YoY. Analysts have raised price targets to $120, citing confidence in the company's execution and profitability. The upcoming launch of the 3870 pumps is expected to drive future growth.
Insider selling has increased significantly by 2147.74% over the last month, which may indicate a lack of confidence from those closest to the company. Technical indicators suggest bearish momentum, and there is no recent news or significant trading signals to support a strong buy decision.
In Q4 2025, IRadimed reported revenue growth of 17.03% YoY, net income growth of 25.16% YoY, and EPS growth of 25.00% YoY. However, gross margin dropped slightly by -1.41% YoY to 75.06%.
Analysts from Lake Street and Roth Capital have raised their price targets to $120, maintaining Buy ratings. They cite strong Q4 results, higher forward estimates, and confidence in the company's execution and future growth prospects.
